XTNT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.531

Open

0.499

VWAP

0.52

Vol

150.31K

Mkt Cap

73.41M

Low

0.494

Amount

77.67K

EV/EBITDA(TTM)

6.47

Total Shares

140.07M

EV

81.79M

EV/OCF(TTM)

6.52

P/S(TTM)

0.58

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.

Show More

Events Timeline

(ET)

2026-04-13

09:10:00

Xtant Medical Acquires Exclusive U.S. Distribution Rights for Dilon's Hemoblast Bellows

2026-03-31 (ET)

2026-03-31

07:10:00

Xtant Medical Sees 2026 Revenue of $95M-$99M

2026-03-31

07:10:00

Xtant Reports Q4 Revenue of $32.4M, Sees Positive Cash Flow in 2026

2026-03-02 (ET)

2026-03-02

08:10:00

Xtant Medical Finalizes $21.4M Asset Sale

2025-12-11 (ET)

2025-12-11

08:10:00

Xtant Medical Launches Strata Synthetic Bone Graft

2025-11-10 (ET)

2025-11-10

16:30:34

Xtant Medical announces Q3 earnings per share of 1 cent compared to a loss of 4 cents last year.

2025-04-16 (ET)

2025-04-16

08:06:25

Xtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65M

News

Newsfilter

04-13Newsfilter

Xtant Acquires Dilon Sales Team to Expand Market Reach

seekingalpha

03-31seekingalpha

Xtant Medical Holdings Reports Q4 2025 Earnings and Strategic Outlook

seekingalpha

03-31seekingalpha

Xtant Medical Q4 Earnings Beat Expectations with Revenue Growth

PRnewswire

2025-12-11PRnewswire

Xtant Medical Launches Next-Gen nanOss Strata™ Synthetic Bone Graft

Businesswire

2025-12-01Businesswire

Companion Spine Acquires Paradigm Spine, Expanding Spine Implant Market Reach

Newsfilter

2025-12-01Newsfilter

Xtant Medical Sells Non-Core Assets for $19.2 Million

2 Analyst Rating

Wall Street analysts forecast XTNT stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

1.50

Averages

1.50

High

1.50

Current: 0.000

Low

1.50

Averages

1.50

High

1.50

Maxim

initiated

$1.50

AI Analysis

2026-04-20

New

Reason

Maxim

Price Target

$1.50

AI Analysis

2026-04-20

New

initiated

Reason

Maxim resumed coverage of Xtant Medical with a Buy rating and $1.50 price target. With the overall focus on the higher-growth and higher-margin orthobiologics business, Xtant is positioned for organic and profitable growth, and may engage in M&A, partnerships, or in-licensing deals, the analyst tells investors in a research note. Xtant is also currently self-financing and does not require a capital raise to continue operations, the firm added.

BTIG

Buy

downgrade

$2

2025-11-11

Reason

BTIG

Price Target

$2

2025-11-11

downgrade

Buy

Reason

BTIG lowered the firm's price target on Xtant Medical to $1.50 from $2 and keeps a Buy rating on the shares. Xtant Medical reported Q3 revenue up 19% year over year and EPS of 1c, slightly above estimates, driven by $5.5M in license revenue, the analyst tells investors in a research note. The company reaffirmed FY25 guidance of $131M-$135M and appears positioned for self-sustained growth, with high single-digit expansion expected in FY26 and beyond, BTIG says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for XTNT

Unlock Now

Valuation Metrics

The current forward P/E ratio for Xtant Medical Holdings Inc (XTNT.A) is 34.84, compared to its 5-year average forward P/E of -11.93. For a more detailed relative valuation and DCF analysis to assess Xtant Medical Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-11.93

Current PE

34.84

Overvalued PE

25.27

Undervalued PE

-49.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

20.39

Current EV/EBITDA

39.05

Overvalued EV/EBITDA

40.78

Undervalued EV/EBITDA

0.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

0.91

Current PS

0.69

Overvalued PS

1.40

Undervalued PS

0.41

Financials

AI Analysis

Annual

Quarterly

Whales Holding XTNT

Nantahala Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Xtant Medical Holdings Inc (XTNT) stock price today?

The current price of XTNT is 0.5241 USD — it has increased 2.75

What is Xtant Medical Holdings Inc (XTNT)'s business?

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.

What is the price predicton of XTNT Stock?

Wall Street analysts forecast XTNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTNT is1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Xtant Medical Holdings Inc (XTNT)'s revenue for the last quarter?

Xtant Medical Holdings Inc revenue for the last quarter amounts to 32.36M USD, increased 2.68

What is Xtant Medical Holdings Inc (XTNT)'s earnings per share (EPS) for the last quarter?

Xtant Medical Holdings Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00

How many employees does Xtant Medical Holdings Inc (XTNT). have?

Xtant Medical Holdings Inc (XTNT) has 151 emplpoyees as of April 25 2026.

What is Xtant Medical Holdings Inc (XTNT) market cap?

Today XTNT has the market capitalization of 73.41M USD.